Skip to Main Content

Author Details

Tobias Sj??blom
Uppsala University
1999
94
31
Emma Lundberg (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37724848Atypical (non-V600E) BRAF mutations in metastatic colorectal cancer in population and real-world cohorts.Int J Cancer2024
36724681An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers.EBioMedicine2023
36980674Exact Probability Distribution for the ROC Area under Curve.Cancers (Basel)2023
37173961Signet Ring Cell Colorectal and Appendiceal Cancer: A Small Signet Ring Cell Component Is Also Associated with Poor Outcome.Cancers (Basel)2023
37463882Next generation pan-cancer blood proteome profiling using proximity extension assay.Nat Commun2023
34261731Profiling chromatin accessibility in formalin-fixed paraffin-embedded samples.Genome Res2022
35805002Iron Chelator VLX600 Inhibits Mitochondrial Respiration and Promotes Sensitization of Neuroblastoma Cells in Nutrition-Restricted Conditions.Cancers (Basel)2022
35406529Next Generation Plasma Proteomics Identifies High-Precision Biomarker Candidates for Ovarian Cancer.Cancers (Basel)2022
35872325Enhanced cytotoxicity of a novel family of ATPase inhibitors in colorectal cancer cells with high NAT2 activity.Biochem Pharmacol2022
35251991<i>KRAS</i>-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer.Front Oncol2022
33450833Targeting Loss of Heterozygosity: A Novel Paradigm for Cancer Therapy.Pharmaceuticals (Basel)2021
33649492Author Correction: Targeted sequencing reveals the somatic mutation landscape in a Swedish breast cancer cohort.Sci Rep2021
33689551Completeness and accuracy of the registration of recurrences in the Swedish Colorectal Cancer Registry (SCRCR) and an update of recurrence risk in colon cancer.Acta Oncol2021
34771707The Immune Landscape of Colorectal Cancer.Cancers (Basel)2021
34534335FACT-seq: profiling histone modifications in formalin-fixed paraffin-embedded samples with low cell numbers.Nucleic Acids Res2021
34233735Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis.J Exp Clin Cancer Res2021
34279175Accurate population-based model for individual prediction of colon cancer recurrence.Acta Oncol2021
33453311Neoadjuvant rectal (NAR) score: Value evaluating the efficacy of neoadjuvant therapy and prognostic significance after surgery?Radiother Oncol2021
32161261Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy.Nat Commun2020
31924107Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis.Acta Oncol2020
31893351Beyond the NCCN Risk Factors in Colon Cancer: An Evaluation in a Swedish Population-Based Cohort.Ann Surg Oncol2020
33375133A Comprehensive Evaluation of Associations Between Routinely Collected Staging Information and The Response to (Chemo)Radiotherapy in Rectal Cancer.Cancers (Basel)2020
33168853Targeted sequencing reveals the somatic mutation landscape in a Swedish breast cancer cohort.Sci Rep2020
33182510Recurrence Risk after Radical Colorectal Cancer Surgery-Less Than before, But How High Is It?Cancers (Basel)2020
33153037Prognostic Interactions between FAP+ Fibroblasts and CD8a+ T Cells in Colon Cancer.Cancers (Basel)2020
33384440Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer.Sci Rep2020
32944621Targeting tumor vulnerabilities associated with loss of heterozygosity.Mol Cell Oncol2020
32471474Restoration of KMT2C/MLL3 in human colorectal cancer cells reinforces genome-wide H3K4me1 profiles and influences cell growth and gene expression.Clin Epigenetics2020
32497306Unexpected Acetylation of Endogenous Aliphatic Amines by Arylamine N-Acetyltransferase NAT2.Angew Chem Int Ed Engl2020
31015111Determining the use of preoperative (chemo)radiotherapy in primary rectal cancer according to national and international guidelines.Radiother Oncol2019
31434940Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series.Sci Rep2019
31432367Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer.Breast Cancer Res Treat2019
31289351Stroma-normalised vessel density predicts benefit from adjuvant fluorouracil-based chemotherapy in patients with stage II/III colon cancer.Br J Cancer2019
28631533U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden.Acta Oncol2018
30027561VEGF receptor-2/neuropilin 1 trans-complex formation between endothelial and tumor cells is an independent predictor of pancreatic cancer survival.J Pathol2018
30201417Stage distribution utilizing magnetic resonance imaging in an unselected population of primary rectal cancers.Eur J Surg Oncol2018
29282718Multispectral imaging for quantitative and compartment-specific immune infiltrates reveals distinct immune profiles that classify lung cancer patients.J Pathol2018
29301589Linking FOXO3, NCOA3, and TCF7L2 to Ras pathway phenotypes through a genome-wide forward genetic screen in human colorectal cancer cells.Genome Med2018
28818916A pathology atlas of the human cancer transcriptome.Science2017
28415818Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity.Oncotarget2017
28108514Somatic Ephrin Receptor Mutations Are Associated with Metastasis in Primary Colorectal Cancer.Cancer Res2017
28094784Targeted DNA sequencing and in situ mutation analysis using mobile phone microscopy.Nat Commun2017
29228717Somatic <i>PRDM2</i> c.4467delA mutations in colorectal cancers control histone methylation and tumor growth.Oncotarget2017
28716088Loss of DIP2C in RKO cells stimulates changes in DNA methylation and epithelial-mesenchymal transition.BMC Cancer2017
26957556Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia.Clin Cancer Res2016
26675346Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.Blood2016
25488813Computational and molecular tools for scalable rAAV-mediated genome editing.Nucleic Acids Res2015
26056301Transcriptional modulator ZBED6 affects cell cycle and growth of human colorectal cancer cells.Proc Natl Acad Sci U S A2015
25864925Tumor vessel up-regulation of INSR revealed by single-cell expression analysis of the tyrosine kinome and phosphatome in human cancers.Am J Pathol2015
24931216In situ sequencing identifies TMPRSS2-ERG fusion transcripts, somatic point mutations and gene expression levels in prostate cancers.J Pathol2014
  • 1 - 50 of 94

Recommended Authors

Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 0
Sander R van Hooff
Princess Maxima Center for Pediatric Oncology
Career Start Year 2008
Number of shared co-authors 0
Salvatore Piscuoglio
University of Basel
Career Start Year 2008
Number of shared co-authors 0
Lawrence N Kwong
The University of Texas MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 0
Nicola Waddell
QIMR Berghofer Medical Research Institute
Career Start Year 2006
Number of shared co-authors 2
Barry S Taylor
Memorial Sloan Kettering Cancer Center
Career Start Year 2006
Number of shared co-authors 3
Albrecht Stenzinger
Institute of Pathology, University Hospital Heidelberg
Career Start Year 2005
Number of shared co-authors 0
Christopher A Bristow
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 1
Jesse S Boehm
Broad Institute of Harvard and MIT
Career Start Year 2004
Number of shared co-authors 1
Obi L Griffith
Washington University
Career Start Year 2003
Number of shared co-authors 2
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2003
Number of shared co-authors 0
Olivier Harismendy
University of California
Career Start Year 2003
Number of shared co-authors 1
Jianhua Zhang
University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 1
Nikolaus Schultz
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 3
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Career Start Year 2002
Number of shared co-authors 2
Michael Slifker
Fox Chase Cancer Center
Career Start Year 2002
Number of shared co-authors 1
Luciano G Martelotto
Monash University
Career Start Year 2000
Number of shared co-authors 0
Kenna R Mills Shaw
The University of Texas MD Anderson Cancer Center
Career Start Year 1999
Number of shared co-authors 2
Li Ding
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 1997
Number of shared co-authors 3
Jan Budczies
Institute of Pathology, University Hospital Heidelberg
Career Start Year 1996
Number of shared co-authors 0
Tatsuhiro Shibata
Kurume University School of Medicine
Career Start Year 1993
Number of shared co-authors 2
Remond J A Fijneman
The Netherlands Cancer Institute
Career Start Year 1993
Number of shared co-authors 1
Arul M Chinnaiyan
University of Michigan Medical School.
Career Start Year 1993
Number of shared co-authors 3
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Career Start Year 1992
Number of shared co-authors 4
Levi A Garraway
Broad Institute of Harvard and MIT
Career Start Year 1991
Number of shared co-authors 2
Phillip A Futreal
The University of Texas MD Anderson Cancer Center
Career Start Year 1991
Number of shared co-authors 3
Todd R Golub
Broad Institute of MIT and Harvard
Career Start Year 1989
Number of shared co-authors 3
Enzo Medico
Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS
Career Start Year 1988
Number of shared co-authors 0
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Career Start Year 1987
Number of shared co-authors 2
Matthew Meyerson
Broad Institute
Career Start Year 1983
Number of shared co-authors 5

Collaborators

Bengt Glimelius
Uppsala University
Co-authored papers 20
Patrick Micke
Uppsala University
Co-authored papers 10
Fredrik Pont??n
Uppsala University
Co-authored papers 10
Per-Henrik Edqvist
Uppsala University
Co-authored papers 8
Victor E Velculescu
Co-authored papers 7
Kenneth W Kinzler
Co-authored papers 7
Mats Nilsson
Stockholm University
Co-authored papers 6
Bert Vogelstein
Co-authored papers 6
Siân Jones
Co-authored papers 5
Helgi Birgisson
The Icelandic Cancer Registry
Co-authored papers 5
Nickolas Papadopoulos
Co-authored papers 4
Giovanni Parmigiani
Dana Farber Cancer Institute.
Co-authored papers 4
Rebecca J Leary
Co-authored papers 4
Donald W Parsons
Texas Children's Hospital
Co-authored papers 4
Sanford D Markowitz
Co-authored papers 4
Mathias Uhl??n
KTH Royal Institute of Technology
Co-authored papers 3
Per Artursson
Department of Pharmacy, Uppsala University
Co-authored papers 3
Karolina Edlund
Leibniz Research Centre for Working Environment and Human Factors at TU Dortmund
Co-authored papers 3
Karin Jirstr??m
Lund University
Co-authored papers 3
Phillip Buckhaults
University of South Carolina
Co-authored papers 3
Ben Ho Park
Vanderbilt University Medical Center
Co-authored papers 3
Kornelia Polyak
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School
Co-authored papers 2
Johanna S M Mattsson
Uppsala University
Co-authored papers 2
Jochen M Schwenk
KTH Royal Institute of Technology
Co-authored papers 2
Simina M Boca
Georgetown University Medical Center
Co-authored papers 2
Jennifer R S Meadows
Co-authored papers 2
Kalle von Feilitzen
KTH Royal Institute of Technology
Co-authored papers 2
Ulf Gyllensten
Co-authored papers 2
Dijana Djureinovic
Yale University School of Medicine
Co-authored papers 2
Jessica Nordlund
Uppsala University
Co-authored papers 2
Release 1.2